The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
121154372 12115437 2 F 20121227 20160822 20160225 20160831 EXP US-ASTRAZENECA-2013SE26044 ASTRAZENECA 24552.00 DY F Y 67.10000 KG 20160831 US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
121154372 12115437 1 SS NEXIUM ESOMEPRAZOLE MAGNESIUM 1 Oral U U 0 20 MG QD
121154372 12115437 2 PS SYMBICORT BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE 1 Respiratory (inhalation) 160/4.5 MCG ONE PUFF TWICE A DAY 21929
121154372 12115437 3 SS SYMBICORT BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE 1 Respiratory (inhalation) 160/4.5 MCG ONE PUFF TWICE A DAY 21929
121154372 12115437 4 C TRIAMTEERIL 2 Oral 37.5 BIWK 0
121154372 12115437 5 C TRIAMETRENE 2 Oral 37.5 BIWK 0
121154372 12115437 6 C GILOTRIF AFATINIB 1 Oral 0 20 MG QD
121154372 12115437 7 C BYSTOLIC NEBIVOLOL HYDROCHLORIDE 1 Oral 0 5 MG QD
121154372 12115437 8 C BYSTOLIC NEBIVOLOL HYDROCHLORIDE 1 Oral 0 2.5 MG QD
121154372 12115437 9 C ZYRTEC CETIRIZINE HYDROCHLORIDE 1 Oral 0 10 MG QD
121154372 12115437 10 C COMBAVENT 2 Respiratory (inhalation) AS REQUIRED 0
121154372 12115437 11 C CELEBREX CELECOXIB 1 Oral 0 200 MG QD
121154372 12115437 12 C CALCIUM CALCIUM 1 Oral 0
121154372 12115437 13 C VITAMIN C ASCORBIC ACID 1 Oral 0
121154372 12115437 14 C PROBIOTIC PROBIOTICS NOS 1 Oral 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
121154372 12115437 1 Dyspepsia
121154372 12115437 2 Asthma
121154372 12115437 3 Asthma
121154372 12115437 4 Hypertension
121154372 12115437 5 Hypertension
121154372 12115437 6 Lung neoplasm malignant
121154372 12115437 7 Hypertension
121154372 12115437 8 Hypertension
121154372 12115437 9 Asthma
121154372 12115437 10 Asthma
121154372 12115437 11 Back pain
121154372 12115437 12 Supplementation therapy
121154372 12115437 13 Supplementation therapy
121154372 12115437 14 Abdominal discomfort

Outcome of event

Event ID CASEID OUTC COD
121154372 12115437 HO
121154372 12115437 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
121154372 12115437 Aphthous ulcer
121154372 12115437 Asthma
121154372 12115437 Cancer pain
121154372 12115437 Diarrhoea
121154372 12115437 Dyspnoea
121154372 12115437 Intentional product misuse
121154372 12115437 Lung carcinoma cell type unspecified stage IV
121154372 12115437 Spinal fracture
121154372 12115437 Wheezing

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
121154372 12115437 1 201601 0
121154372 12115437 2 20110909 201412 0
121154372 12115437 3 201607 0
121154372 12115437 6 201507 0
121154372 12115437 9 201508 0